Update for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis

Abstract

AbstractBackgroundThe landscape of biologic agents for the treatment of inflammatory bowel disease (IBD) associated colitis is rapidly evolving, requiring surgeons to be up‐to‐date as part of multi‐disciplinary, evidence‐based care. An update on novel therapies used to induce remission in IBD‐associated colitis is presented.MethodsA systematic search through Ovid MEDLINE and CENTRAL using a combination of MeSH terms and Boolean operators was conducted.ResultsOne thousand and twenty articles from which 38 articles were selected for inclusion in this review. Novel agents were trialled as 4th or 5th line treatment following conventional treatment failure. Rates of serious adverse effects were low. Janus kinase (JAK) inhibitors (upadacitinib and tofacitinib) were efficacious in inducing remission in ulcerative colitis, and IL‐23p19 inhibitors (mirikizumab, guselkumab, and risankizumab) in Crohn's colitis. Evidence was limited for other drug classes.ConclusionJAK‐inhibitors and IL‐23p19 inhibitors were found to be the most effective agents for inducting remission following failure of standard of care treatment. A significant proportion of patients did not respond, highlighting the inherent challenge in optimizing treatment for moderate to severe IBD‐associated colitis. More robust study designs and comparator trials are required.